Abstract

BackgroundPhase III trial data have shown a significant benefit by the addition of a maintenance treatment with niraparib, irrespective of BRCA or HRD status, in patients with advanced high-grade ovarian...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
AGO-OVAR 28/ENGOT-ov57: Niraparib versus niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer—A multicenter, randomized, phase III trial.
Stephanie Henry ... David Cibula
Journal of Clinical Oncology | VOL. 40
Stephanie Henry, et. al.Stephanie Henry ... David Cibula
01 Jun 2022
State of the art of surgery in advanced epithelial ovarian cancer
N.F Hacker
Annals of Oncology | VOL. 24
N.F HackerN.F Hacker
01 Dec 2013
Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer
Anil K Sood ... Bryan M Fellman
Gynecologic Oncology | VOL. 161
Anil K Sood, et. al.Anil K Sood ... Bryan M Fellman
16 Apr 2021
2022-RA-909-ESGO AGO-OVAR 28/ENGOT-ov57: niraparib vs niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer (a multicentre randomised phase III trial)
Sandra Polleis ... Nicoletta Colombo
International Journal of Gynecologic Cancer | VOL. 32
Sandra Polleis, et. al.Sandra Polleis ... Nicoletta Colombo
01 Oct 2022
View more papers

More From: International Journal of Gynecologic Cancer

Paper Title
Journal
Date
Author
Can international standards in ovarian cancer treatment be attained by low- and middle-income countries?
Daniel Sanabria ... Adriana Ramos
International Journal of Gynecologic Cancer | VOL. -
Daniel Sanabria, et. al.Daniel Sanabria ... Adriana Ramos
24 May 2024
Prognosis of isolated tumor cells and use of molecular classification in early stage endometrioid endometrial cancer
Eric Rios-Doria ... Mario M Leitao
International Journal of Gynecologic Cancer | VOL. -
Eric Rios-Doria, et. al.Eric Rios-Doria ... Mario M Leitao
23 May 2024
A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC)
Agnieszka Michael ... Jonathan Ledermann
International Journal of Gynecologic Cancer | VOL. -
Agnieszka Michael, et. al.Agnieszka Michael ... Jonathan Ledermann
17 May 2024
Predictive value of SUVmax from initial 18F-FDG PET/CT scans for treatment outcomes in endometrial cancer patients undergoing fertility sparing management
Ok-Ju Kang ... Jeong-Yeol Park
International Journal of Gynecologic Cancer | VOL. -
Ok-Ju Kang, et. al.Ok-Ju Kang ... Jeong-Yeol Park
16 May 2024
View more papers